What is Iantrek?
Founded by ophthalmic innovator Dr. Sean Ianchulev, Iantrek is a venture-backed medical technology enterprise dedicated to pioneering bio-interventional and micro-interventional products. The company's core mission centers on transforming the management of glaucoma through a sophisticated portfolio of solutions, including AlloSert Uveo, AlloFlo Uveo, CanaloFlo, and C.Rex. By focusing on minimally invasive techniques, Iantrek addresses significant unmet needs in ophthalmology, positioning itself at the intersection of cutting-edge biology and surgical precision. Its market position is bolstered by a commitment to clinical excellence and the development of technologies that improve patient outcomes in underserved segments of the eye care industry.
How much funding has Iantrek raised?
Iantrek has raised a total of $135M across 5 funding rounds:
Series A
$5.2M
Series B
$23M
Series C
$42M
Stock/Share Issuance
$34.7M
Debt
$30M
Series A (2020): $5.2M, investors not publicly disclosed
Series B (2022): $23M led by Sectoral Asset Management and Visionary Ventures
Series C (2025): $42M supported by Visionary Ventures, aMoon, Sectoral Asset Management, and US Venture Partners
Stock/Share Issuance (2025): $34.7M, investors not publicly disclosed
Debt (2026): $30M backed by Trinity Capital
Key Investors in Iantrek
Visionary Ventures
Visionary Ventures is an Orange County-based venture capital firm that leverages a unique information advantage approach to connect capital and insight with promising life sciences and ophthalmology startups.
Sectoral Asset Management
Sectoral Asset Management is an investment advisor specializing in managing equities globally within the healthcare sector, offering a range of public and private equity strategies.
aMoon
aMoon is a healthcare investment firm that partners with exceptional scientists and entrepreneurs to build companies focused on transforming healthcare through technology and biology.
What's next for Iantrek?
With the recent influx of capital, Iantrek is well-positioned to transition into a new phase of operational expansion and product commercialization. The strategic focus will likely shift toward broadening the clinical adoption of its existing portfolio and advancing the regulatory pathways for its pipeline technologies. As the company scales, it will leverage its strong relationships with institutional investors to navigate the complexities of the global healthcare market. The continued support from specialized life sciences investors suggests a long-term commitment to establishing Iantrek as a dominant force in the ophthalmic surgical landscape, with a clear emphasis on sustainable growth and technological disruption.
See full Iantrek company page
